Search the Newsreel

RenovoRx (NASDAQ:RNXT) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded RenovoRx (NASDAQ:RNXT) from a "sell" to a "hold" rating, while the overall analyst consensus remains a "Moderate Buy" with an $8.50 average price target. The company reported a narrower-than-expected quarterly loss of $0.05 per share and revenues of $0.91 …

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

Wall Street Zen has upgraded Vor Biopharma (NASDAQ:VOR) from a "sell" to a "hold" rating. Despite this, the overall analyst consensus for Vor Biopharma remains a "Moderate Buy" with an average price target of $43.38, though the company's stock trades significantly below its 52-week …

Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership

Frazier Life Sciences-affiliated funds have filed an amended Schedule 13G indicating beneficial ownership of less than 5% of Vor Biopharma Inc. common stock. Frazier Life Sciences Public Fund, L.P. holds 4.2% of the class, while Frazier Life Sciences XII, L.P. holds 0.5%, and Frazier …

Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake

A Venrock-led group, including Venrock Healthcare Capital and individuals Nimish Shah and Bong Koh, has reported a beneficial ownership stake of 9.99% in Vor Biopharma Inc. (VOR). This stake comprises 5,676,370 shares of common stock, including Pre-Funded Warrants, as of June 30, 2026. A …

Vornado Realty Trust Stock 12‑Month Price Target Raised to $40.38, Implies 2% Upside

Analysts have raised the 12-month average price target for Vornado Realty Trust (VNO) stock from $40.15 to $40.38, indicating a potential 2% upside from its Aug. 13 closing price. This new target is based on estimates from 13 analysts, with individual forecasts ranging from …

Vornado Realty: PENN District Drives Remarkable Quarter For Leasing Volume (NYSE:VNO)

VOR|Vor Biopharma Inc|Price:23.260|Chg%:+0.920

Verve Capital Limited (VOR) reports 6.3% stake in Vor Biopharma common stock

Verve Capital Limited has reported a 6.3% beneficial ownership stake in Vor Biopharma Inc. (VOR) common stock as of June 30, 2026. This ownership includes 3,410,892 shares, with Verve Capital holding sole voting and dispositive power. The filing, an amended SCHEDULE 13G/A, was signed …

VOR BIOPHARMA INC. : WEDBUSH RAISES TARGET PRICE TO $27 FROM $18

Wedbush has increased its target price for VOR Biopharma Inc. from $18 to $27. This adjustment reflects a more optimistic outlook on the company's financial prospects by the analyst firm. The article is a brief news update published on Webull.

Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright

HC Wainwright has reduced its FY2030 EPS forecast for Vor Biopharma to $3.89 from $4.27, though it maintained a "Buy" rating and a $31 price target. The company recently reported quarterly EPS of -$0.80, missing the consensus estimate. Despite the lowered forecast, the overall …

Does Vornado Realty Trust (VNO) Change Its Manhattan Growth Case With 350 Park Avenue?

Vornado Realty Trust (NYSE:VNO) has partnered with Rudin Management and Kenneth Griffin's affiliate for a new 1.9 million sq ft office development at 350 Park Avenue in Manhattan, with Vornado holding a 36% stake and leading development. This project aligns with Vornado's strategy of …

Vor Biopharma (VOR) Stock Looks Reasonable On Earnings Yet Weak On Broader Checks

RenovoRx earnings beat by $0.02, revenue topped estimates

Related, Vornado Face 'Imminent Default' At 85 10th Ave.

A $396M mortgage tied to the 85 10th Ave. office building, co-owned by Vornado Realty Trust and Related Cos., has been transferred to special servicing due to potential "imminent default" and cash flow concerns. The property, anchored by Google, is 89.9% occupied, but its …

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates

RenovoRx, Inc. (RNXT) reported a Q2 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.08 loss and an improvement from last year's $0.08 loss. The company also exceeded revenue estimates, posting $0.91 million against an expected $0.73 million. Despite outperforming …

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

RenovoRx announced record financial results for the second quarter of 2026, with revenue reaching $909,000, marking a 61% sequential quarterly increase and a 115% year-over-year increase. The company raised its 2026 annual revenue guidance to a range of $3.75 million to $4.25 million, driven …

RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Beats Estimates By $0.02 EPS

RenovoRx (NASDAQ:RNXT) reported a narrower-than-expected quarterly loss of $0.05 per share, surpassing consensus estimates by $0.02. The company also saw significant revenue growth, climbing 61% sequentially and 115% year-over-year to $909,000, leading management to raise its 2026 revenue guidance. Despite this progress, RenovoRx remains …

Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance

RenovoRx announced a strong Q2 2026 performance, exceeding Wall Street expectations with higher-than-forecasted revenue of $909,000 and a smaller loss of 6 cents per share. The medical device company raised its full-year 2026 revenue guidance to $3.75 million to $4.25 million, citing record quarterly …

International Flavors & Fragrances Inc. stock underperforms Wednesday when compared to competitors

International Flavors & Fragrances Inc. (IFF) stock dropped 1.35% to $83.85 on Wednesday, marking its third consecutive day of losses. This underperformance occurred during a mixed trading session where the S&P 500 Index saw a slight gain, while the Dow Jones Industrial Average experienced …

Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price

Wedbush has increased its price target for Vor Biopharma (NASDAQ:VOR) to $27 from $18, while maintaining a neutral rating, suggesting a potential 21% upside. Despite this positive target, the company missed its recent quarterly earnings estimates, reporting a loss of $0.80 per share against …

VOR Maintains Rating by Wedbush -- Price Target Raised to $27.00

Wedbush has maintained its Neutral rating on Vor Biopharma (VOR) but significantly increased its price target from $18.00 to $27.00, suggesting potential for growth despite a cautious outlook. The company, a clinical-stage biopharmaceutical firm focusing on autoimmune diseases, has a low GF Score™ of …

Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings

Vor Biopharma (NASDAQ:VOR) experienced a 6.5% drop in stock price following an earnings announcement where the company reported a quarterly EPS of negative $0.80, missing the consensus estimate of negative $0.69. Despite the disappointing earnings and reduced trading volume, the company maintains a "Moderate …

Friedrich Vorwerk übernimmt meterQ - Ausbau des Wasserstoffgeschäfts

RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...

RenovoRx Inc (RNXT) reported record Q2 2026 revenue of $909,000, a 61% sequential and 115% year-over-year increase, driven by an expanded commercial presence in cancer centers. The company also announced full enrollment for its Phase 3 TIGERPAC trial, with top-line data expected in late …

Pacer Advisors Inc. Sells 1,478,726 Shares of Vornado Realty Trust $VNO

Pacer Advisors Inc. significantly reduced its stake in Vornado Realty Trust (NYSE:VNO) by 98.8% in the first quarter, selling over 1.4 million shares and retaining 18,570 shares. Despite missing analyst EPS estimates, Vornado's revenue increased by 4.7% year-over-year, and the company authorized a $300 …

First Trust Advisors LP Decreases Position in Vornado Realty Trust $VNO

First Trust Advisors LP reduced its stake in Vornado Realty Trust (NYSE:VNO) by 64.6% in the first quarter, selling over 41,000 shares. Despite this, other institutional investors have recently acquired positions in Vornado. The company reported mixed quarterly results, missing EPS estimates but exceeding …

Projeções de Resultados: International Flavors & Fragrances Inc (IFF) — LPA e Crescimento de Receita

Citadel Will Anchor 350 Park Avenue With 15-Year, 1.05M-Sq.-Ft. Lease

Vornado Realty Trust (NYSE: VNO) announced a joint venture with Rudin Management and an affiliate of Kenneth C. Griffin to develop a 1.9 million square foot trophy office tower at 350 Park Avenue in New York. Citadel Enterprise Americas LLC will serve as the …

Vornado Realty teams up with Ken Griffin for $6.2B project at 350 Park Avenue (VNO:NYSE)

Vornado Realty Trust and Rudin Management are forming a joint venture with an affiliate of Ken Griffin, founder of Citadel, for a $6.2 billion development. The project involves a 1.9 million square-foot trophy office building at 350 Park Avenue. This partnership signifies a major …

Vornado Realty Trust to Enter into 350 Park Avenue Joint Venture

Vornado Realty Trust and Rudin Management have partnered with Kenneth C. Griffin of Citadel to develop a 1.9 million square foot trophy office building at 350 Park Avenue. Citadel Enterprise Americas LLC will anchor the building with a 15-year lease for 1.05 million square …

Vornado (VNO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Steven Roth President and Chief Financial Officer - Michael Franco Executive Vice President and Corporation Counsel - Steven Borenstein Full Conference Call …

Vor Biopharma (NASDAQ:VOR) Posts Earnings Results

Vor Biopharma (NASDAQ:VOR) reported a Q2 loss of $0.80 per share, missing consensus estimates by $0.11. Shares closed down $0.39 at $22.98, though the stock remains well above its 52-week low. Analysts maintain a "Moderate Buy" rating with an average price target of $42.25, …

Vor Biopharma (VOR) Strengthens Cash Position Amid Unprofitable Operations